BioSpace News Archive

Increasing demand for genetic testing in fetuses due to growing incidences of genetic disorders, integration of advanced bioinformatics to provide accurate information about the baby, and rising need for non-invasive testing methods are some key factors expected to drive Non-Invasive Prenatal Testing market growth.

Today, MedMira Inc. (MedMira) (TSXV: MIR) launches its Reveal® TP (Syphilis) product in Europe and gets clinical trials underway in Canada.

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting.

In March 2022, DeoBioSciences, a cancer drug biotech start-up, is concluding its first equity crowdfunding offering to individual and institutional investors at Netcapital.com.

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan D’Alvise, President and Chief Executive Officer of Acasti Pharma will be presenting at the 32nd Annual Oppenheimer Healthcare conference being held virtually March 15-17, 2022.

DENTSPLY SIRONA Inc. announced that it has entered into an accelerated share repurchase agreement with Bank of America, National Association to repurchase $150 million of its common stock.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis, will attend the 34th Annual ROTH Conference.

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Convergent Therapeutics, Inc., a clinical stage radiopharmaceutical company, today announced the signing of a long-term supply agreement for the therapeutic medical radioisotope, actinium-225 (Ac-225).

Vaccinex, Inc. announced that it has been selected for poster presentation related to the phase 1b segment of its KEYNOTE-B84 study of pepinemab in combination with KEYTRUDA in patients with recurrent or metastatic head and neck cancer during the upcoming 2022 American Association for Cancer Research Meetings, taking place from April 8th to April 13th in New Orleans via in person and virtual attendance.

U.S. Stem Cell, Inc., a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions has appointed Mark Borman as Chairman of the Board as Dr. William P. Murphy Jr transitions to Chairman Emeritus.